Pharmaceutical News

RSS

Federal appellate court rules in favor of Merck in TEMODAR patent infringement suit

Merck & Co., Inc. said today that a federal appellate court ruled in its favor in a TEMODAR patent infringement suit against Barr Laboratories, an affiliate of Teva Pharmaceuticals.

10 Nov 2010

Baxa launches ExactaMix 1200 Automated Compounding Device

Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations, today introduced the ExactaMix 1200 Automated Compounding Device (ACD) for small- to mid-sized hospital pharmacies in need of an automated approach to compounding large-volume parenteral doses.

9 Nov 2010

Semafore's SF1126 for B-cell chronic lymphocytic leukemia granted FDA orphan drug designation

Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).

9 Nov 2010

Provectus holds second meeting with Australian TGA to review approval of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has held its second meeting with the Australian Therapeutic Goods Administration ("TGA") to discuss milestones for approval of PV-10 for treatment of metastatic melanoma. The TGA is the part of the Australian Government's Department of Health and Ageing responsible for the assessment, approval and monitoring of therapeutic goods available in Australia. The initial meeting with the TGA was held in October 2008.

9 Nov 2010

Research report on current and evolving technologies in drug delivery

The drug delivery market is a rapidly evolving force in the pharmaceutical industry. Within this segment injectables have a significant role to play at present with the increasing use of proteins and peptides.

9 Nov 2010

EUSA completes BLA filing for ERWINASE in treatment of acute lymphoblastic leukemia

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ERWINASE(R) (L-asparaginase derived from Erwinia chrysanthemi) for use in the treatment of acute lymphoblastic leukemia in patients with hypersensitivity to E. coli-derived asparaginase.

9 Nov 2010

Ultrasound needle guidance improves performance and outcomes of knee injections

The use of ultrasound needle guidance improves the performance, outcomes and the cost-effectiveness of knee injections in people with osteoarthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

Fake antimalarial medications uncovered across Ghana

Substandard and counterfeit versions of thirteen key antimalarial medicines were uncovered in multiple locations across Ghana by the Medicines Quality Monitoring surveillance program. Set up by the Ghana Food and Drugs Board (FDB) in collaboration with the U.S. Pharmacopeial Convention (USP) and the U.S. Agency for International Development (USAID), the program samples antimalarials across the public and private sectors.

9 Nov 2010

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Today, Intercell AG announced its financial results for the third quarter of 2010 and presented an update on the Company's key R&D programs as well as changes to the Management Board.

9 Nov 2010

Combination treatment with methotrexate and prednisone achieves remission in newly-developed RA

People with newly-developed rheumatoid arthritis or undifferentiated arthritis may be able to achieve remission, with continued drug therapy, after four months of treatment with methotrexate and prednisone, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

Scientists develop nanobioconjugate drug to target brain tumor

Nine years ago, scientists at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute detected a subtle shift occurring in the molecular makeup of the most aggressive type of brain tumors, glioblastoma multiforme. With further study, they found that a specific protein called laminin-411 plays a major role in a tumor's ability to build new blood vessels to support its growth and spread. But technology did not exist then to block this protein.

9 Nov 2010

Cook Medical's controlled-release esophageal stent receives FDA clearance

Cook Medical's controlled-release esophageal stent fully covered in silicone has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), making available yet another advanced solution from Cook Medical, the only full-line supplier of endoscopic devices.

9 Nov 2010

EpiCept third quarter net loss decreases to $3.2 million

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2010, and provided an update with respect to the Company's key business initiatives.

9 Nov 2010

Epeius receives competitive grant to support Rexin-G oncology product

Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, announced today the receipt of additional financial support for the company's lead oncology product, Rexin-G, from the U.S. Departments of Treasury, Health and Human Services (HHS), and the National Institutes of Health (NIH) in the form of a prestigious competitive grant.

9 Nov 2010

CMS to review cancer vaccine, analysis shows high Medicare drug spending not correlated with better care

The Centers for Medicare & Medicaid Services are conducting an unusual review to determine whether the government should pay for an expensive new vaccine for treating prostate cancer, rekindling debate over whether some therapies are too costly.

9 Nov 2010

Advaxis collaborates with UBC to develop live attenuated Listeria vaccines

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has entered into a structured collaboration with the laboratory of Dr. Tobias Kollmann at the University of British Columbia (UBC) to develop live attenuated Listeria vaccines for the treatment of infectious disease and for new dosage forms of Listeria vaccines.

9 Nov 2010

Teens abuse prescription drugs more than illegal drugs

According to the 2006 National Survey on Drug Use and Health, teens abuse prescription medications more than all illegal drugs combined, excluding marijuana. Many teens are under the misconception that these highly addictive, easily accessible drugs are "safer" than illicit drugs.

9 Nov 2010

Study finds anti-gout medication may reduce risk of colorectal cancer

Allopurinol, a relatively inexpensive anti-gout medication that has been on the market for more than 20 years, may have some activity against colorectal adenomas, according to data presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held here Nov. 7-10, 2010.

8 Nov 2010

Gents renews distribution agreement for AcnEase with Herborium

Herborium Group, Inc., a Botanical Therapeutics™ company, during its shareholder conference call yesterday afternoon, announced that Gents, AB of Helsingborg, Sweden, renewed its distribution agreement to supply AcnEase® throughout Sweden.

8 Nov 2010

Blocking beta glucuronidase enzyme could eliminate side effects of CPT-11 in colon cancer treatment

A debilitating side effect of a widely used but harshly potent treatment for colon cancer could be eliminated if a promising new laboratory discovery bears fruit.

8 Nov 2010

Pharmaceutical News

Federal appellate court rules in favor of Merck in TEMODAR patent infringement suit

Baxa launches ExactaMix 1200 Automated Compounding Device

Semafore's SF1126 for B-cell chronic lymphocytic leukemia granted FDA orphan drug designation

Provectus holds second meeting with Australian TGA to review approval of PV-10 for metastatic melanoma

Research report on current and evolving technologies in drug delivery

EUSA completes BLA filing for ERWINASE in treatment of acute lymphoblastic leukemia

Ultrasound needle guidance improves performance and outcomes of knee injections

Fake antimalarial medications uncovered across Ghana

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Combination treatment with methotrexate and prednisone achieves remission in newly-developed RA

Scientists develop nanobioconjugate drug to target brain tumor

Cook Medical's controlled-release esophageal stent receives FDA clearance

EpiCept third quarter net loss decreases to $3.2 million

Epeius receives competitive grant to support Rexin-G oncology product

CMS to review cancer vaccine, analysis shows high Medicare drug spending not correlated with better care

Advaxis collaborates with UBC to develop live attenuated Listeria vaccines

Teens abuse prescription drugs more than illegal drugs

Study finds anti-gout medication may reduce risk of colorectal cancer

Gents renews distribution agreement for AcnEase with Herborium

Blocking beta glucuronidase enzyme could eliminate side effects of CPT-11 in colon cancer treatment

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News